Home › Alzheimer's Disease › NCT07701161

Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

Who can join

Ages 40 to 90 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed

Exclusion Criteria:

* Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use

About the study

This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.

Sponsor: Neurogen Biomarking LLC · Participants: 1,000 · Started: Jan 13, 2025

Contact the study team

• Ansam Eghzawi, MD · Phone: +18109410076
• Elisabeth Thijssen, PhD · Phone: +16282788161

Official record on ClinicalTrials.gov — NCT07701161

Locations in the U.S.

Conditions

• Alzheimer's Disease
• Dementia

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.